KRAS G12V NSCLC shows strong smoking link, high co-mutations, and improved outcomes with immunotherapy, especially in PD-L1 high tumors KRAS G12V–Mutated NSCLC: Smoking-Driven Biology and Immunotherapy Sensitivity KRAS G12V is one of the most common KRAS mutations in non–small cell...
KRAS G12V–Mutated NSCLC: Smoking-Driven Biology and Immunotherapy Sensitivity KRAS G12V is one of the most common KRAS mutations in non–small cell lung cancer (NSCLC), yet its clinical behavior and therapeutic implications remain insufficiently defined. This study provides a comprehensive analysis...
In a phase 1 trial published in New England Journal of Medicine in March 2026, the investigational drug setidegrasib showed encouraging antitumor activity in patients with advanced cancers driven by the KRAS G12D mutation, including non-small cell lung cancer (NSCLC)...
Setidegrasib shows early promise in KRAS G12D-mutated lung and pancreatic cancers A first-in-human study finds a novel KRAS G12D–targeted protein degrader produces encouraging responses, particularly in previously treated NSCLC. in March 2026, the investigational drug setidegrasib showed encouraging antitumor activity...
Cetuximab plus fulzerasib or sotorasib enhanced antitumor activity in KRAS G12C NSCLC models, supporting EGFR cotreatment strategies KRAS G12C NSCLC: Promising Strategy as Cetuximab Boosts KRAS Inhibitor Response KRAS G12C NSCLC has entered the era of targeted therapy, but the...
In a phase I trial reported in The New England Journal of Medicine, Park et al identified the toxicity profile and preliminary antitumor activity of setidegrasib, a first-in-class KRAS G12D–targeted protein degrader, in patients with previously treated advanced non–small cell...
Stephen Liu: First-Line Immunotherapy in KRAS G12C NSCLC Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on shared a post on X:....
Stephen Liu: First-Line Immunotherapy in KRAS G12C NSCLC / Alessandra Bearz, Ana Giménez-Capitán, Anna Koumarianou, cancer, Chiara Lazzari, Congqiao Zhao, Stephen Liu/X Stephen Liu: First-Line Immunotherapy in KRAS G12C NSCLC Stephen Liu, Director of Thoracic Oncology, Chief of the Division...
A Phase 1 clinical trial concluded that setidegrasib targets KRAS G12D mutations effectively, showing promise for lung and pancreatic cancer patients The Florida Cancer Specialists & Research Institute (FCS) has recently participated in a Phase 1 clinical study that sheds...
